Clinical Trial Update: Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of docetaxel and imatinib mesylate in metastatic castration-resistant prostate cancer that progressed on prior docetel …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Docetaxel (Taxotere) (docetaxel)
• Imatinib Mesylate (Gleevec) (Imatinib mesylate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Cancer, Prostate Cancer | Phase 2 | Status: COMPLETED